- Health and well-being
Welcome to the next Finnish Cancer Center FICAN Science Webinar with Professor Pekka Taimen (University of Turku & Turku University Hospital).
This time the seminar is hosted by FICAN West. These nationwide webinars provide a platform to share new scientific findings, highlight recent advances in cancer research, and foster collaboration among cancer researchers and clinicians across Finland.
Abstract
Pekka Taimen, MD, PhD, is Professor of Molecular Pathology at the Institute of Biomedicine, University of Turku, and Chief Physician at the Department of Pathology, Turku University Hospital. His translational pathology research group focuses on biomarkers, steroidomics, and patient-derived cell culture models of bladder cancer. Their research on prostate cancer aims to improve diagnostic accuracy and risk stratification by integrating MRI/PET imaging with histopathological data, while lung cancer research has focused on cancer genomics and predictive biomarkers. In addition, Taimen's laboratory investigates the pathobiology of familial cardiomyopathy caused by pathogenic variants in the LMNA gene, which encodes the nuclear intermediate filament proteins known as lamins.
In this webinar, Professor Taimen will present their recent advances in bladder cancer research, including the development of patient-derived cell culture models for drug sensitivity testing, as well as projects involving steroid hormone and transcriptomic profiling.
Relevant references from the speaker for this talk:
• Patient-derived conditionally reprogrammed cells for bladder cancer modeling and drug sensitivity assessment. Saarikoski K, Askari A, Erkkilä S, Keski-Oja T, Vainio P, Nurminen A, Lamminen T, Suhonen J, Rantala JK, Boström PJ, Kettunen K, Taimen P, Turku Prostate Cancer Consortium (2026). npj Precision Oncology, in press.
• Prediction of platinum-based neoadjuvant chemotherapy response in muscle-invasive bladder cancer using a multifaceted approach. Askari A, Mahmoudian M, Lamminen T, Heuser V, Koskinen I, Mirtti T, Elo LL, Schleutker J, Taimen P, Boström PJ (2026). Scientific Reports, 16:36990. https://doi.org/10.1038/s41598-026-64713-3.
• Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study. Kettunen K, Mathlin J, Lamminen T, Laiho A, Häkkinen MR, Auriola S, Elo LL, Boström PJ, Poutanen M, Taimen P (2024).. eBioMedicine 108:105359. https://doi.org/10.1016/j.ebiom.2024.105359.
• Personalized drug sensitivity screening for bladder cancer using conditionally reprogrammed patient-derived cells. Kettunen K, Boström PJ, Lamminen T, Heinosalo T, West G, Saarinen I, Kaipio K, Rantala J, Albanese C, Poutanen M, Taimen P (2019). European Urology 76:430-434. https://doi.org/10.1016/j.eururo.2019.06.016.
For more information, please contact [email protected].